Myovant Sciences Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$7.1M
Doctors Paid
21,256
Transactions
78,555
2022 Total
$3.0M
Payment Breakdown by Category
Research$2.0M (28.8%)
Food & Beverage$1.5M (21.7%)
Consulting$1.1M (15.2%)
Travel$184,990 (2.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.1M | 872 | 29.5% |
| Unspecified | $2.0M | 604 | 28.8% |
| Food and Beverage | $1.5M | 73,964 | 21.7% |
| Consulting Fee | $1.1M | 138 | 15.2% |
| Travel and Lodging | $184,990 | 533 | 2.6% |
| Grant | $105,530 | 3 | 1.5% |
| Education | $48,677 | 2,441 | 0.7% |
Payments by Type
General
$5.0M
77,951 transactions
Research
$2.0M
604 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| HERO STUDY GRANT | $843,973 | 0 | 119 |
| AN INTERNATIONAL PHASE 3 DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY OF RELUGOLIX WITH ESTRADIOL AND NORETHINDRONE ACETATE IN WOMEN WITH HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE FIBROIDS | $462,985 | 0 | 211 |
| AN INTERNATIONAL PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY TO EVALUATE RELUGOLIX ADMINISTERED WITH AND WITHOUT LOW DOSE ESTRADIOL AND NORETHINDRONE ACETATE IN WOMEN WITH HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE FIBROIDS | $211,652 | 0 | 16 |
| SPIRIT EXTENSION: AN INTERNATIONAL PHASE 3 OPEN-LABEL, SINGLE-ARM, SAFETY AND EFFICACY EXTENSION STUDY TO EVALUATE RELUGOLIX ADMINISTERED WITH LOW-DOSE ESTRADIOL AND NORETHINDRONE ACETATE IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN | $198,462 | 0 | 129 |
| SPIRIT EXTENSION AN INTERNATIONAL PHASE 3 OPEN-LABEL, SINGLE-ARM, SAFETY AND EFFICACY EXTENSION STUDY TO EVALUATE RELUGOLIX ADMINISTERED WITH LOW-DOSE ESTRADIOL AND NORETHINDRONE ACETATE IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN | $144,740 | 0 | 77 |
| LIBERTY EXTENSION: AN INTERNATIONAL PHASE 3 OPEN-LABEL, SINGLE-ARM, LONG-TERM EFFICACY AND SAFETY EXTENSION STUDY TO EVALUATE RELUGOLIX CO-ADMINISTERED WITH LOW-DOSE ESTRADIOL AND NORETHINDRONE ACETATE IN WOMEN WITH HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE FIBROIDS | $81,483 | 0 | 23 |
| A PROSPECTIVE OBSERVATIONAL STUDY OF BONE MINERAL DENSITY IN WOMEN WITH UTERINE FIBROIDS OR ENDOMETRIOSIS | $34,046 | 0 | 11 |
| SPIRIT 1: AN INTERNATIONAL PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY TO EVALUATE RELUGOLIX ADMINISTERED WITH AND WITHOUT LOW-DOSE ESTRADIOL AND NORETHINDRONE ACETATE IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN | $30,568 | 0 | 10 |
| SPIRIT 2: AN INTERNATIONAL PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY TO EVALUATE RELUGOLIX ADMINISTERED WITH AND WITHOUT LOW-DOSE ESTRADIOL AND NORETHINDRONE ACETATE IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN | $22,249 | 0 | 6 |
| PUBLICATION DEVELOPMENT SUPPORT IN RELATION TO THE HISTORICAL OVERVIEW OF METASTATIC PROSTATE CANCER THERAPY AND GONADTROPIN-RELEASING HORMONE ANTAGONISTS INCLUDING RELUGOLIX | $3,075 | 1 | 1 |
| SPIRIT 1 AN INTERNATIONAL PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EFFICACY AND SAFETY STUDY TO EVALUATE RELUGOLIX ADMINISTERED WITH AND WITHOUT LOW-DOSE ESTRADIOL AND NORETHINDRONE ACETATE IN WOMEN WITH ENDOMETRIOSIS-ASSOCIATED PAIN | $2,019 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Dr. Bunan Alnaif, Md, MD | Obstetrics & Gynecology | Chesapeake, VA | $32,003 | $0 |
| Dr. Billy Catherino, M.d., Ph.d, M.D., PH.D | Reproductive Endocrinology | Bethesda, MD | $29,873 | $0 |
| Dr. Tim Richardson, Md, MD | Urology | Wichita, KS | $29,480 | $0 |
| Lawrence Gervasi, Md, MD | Urology | Middleburg Heights, OH | $28,776 | $0 |
| Mr. Charles Kirkham, Md, MD | Obstetrics & Gynecology | Corpus Christi, TX | $28,209 | $0 |
| Ayman Al-Hendy | Obstetrics & Gynecology | Chicago, IL | $24,970 | $0 |
| Ganesh Raj, Md Phd, MD PHD | Urology | Victoria, TX | $24,676 | $0 |
| Dr. Damian Sorce, Md, MD | Urology | Parker, CO | $23,210 | $0 |
| Dr. Steven Bonin, Md, MD | Diagnostic Radiology | Duluth, MN | $22,269 | $0 |
| Dr. Laura Mckain, Md, MD | Obstetrics & Gynecology | Wilmington, NC | $22,036 | $0 |
| Dr. Kathleen Zhang, Md, MD | Internal Medicine | Dallas, TX | $21,573 | $0 |
| Dr. David Morris, Md, MD | Student in an Organized Health Care Education/Training Program | Hendersonville, TN | $21,059 | $0 |
| Dr. Jacek Pinski, M.d, M.D | Medical Oncology | Los Angeles, CA | $20,958 | $0 |
| Dr. Alyse Kelly-Jones, Md, MD | Gynecology | Charlotte, NC | $20,855 | $0 |
| Dr. Ashley Ross | Urology | Chicago, IL | $20,346 | $0 |
| Paul Dato, M.d, M.D | Urology | La Mesa, CA | $19,492 | $0 |
| Daniel Voglewede, M.d, M.D | Urology | El Paso, TX | $18,532 | $0 |
| Mr. Jay Kim, Md, MD | Urology | Durham, NC | $17,611 | $0 |
| Soheil Amin-Hanjani, M.d, M.D | Obstetrics & Gynecology | Brockton, MA | $16,904 | $0 |
| Lawrence Karsh, M.d, M.D | Urology | Denver, CO | $16,245 | $0 |
| Dr. Amy Egan, M.d, M.D | Clinic/Center | Bonita Springs, FL | $16,200 | $0 |
| Jessica Shepherd, M.d, M.D | Gynecology | Dallas, TX | $15,615 | $0 |
| Dr. Alec Koo, M.d, M.D | Urology | Torrance, CA | $15,480 | $0 |
| Paul Sieber, M.d, M.D | Urology | Lancaster, PA | $14,940 | $0 |
| Dr. Benjamin Martin, Md, MD | Urology | Gahanna, OH | $14,102 | $0 |
Ad
Top Products
- ORGOVYX $3.1M
- MYFEMBREE $2.3M
Payment Categories
- Food & Beverage $1.5M
- Consulting $1.1M
- Travel & Lodging $184,990
- Research $2.0M
About Myovant Sciences Inc.
Myovant Sciences Inc. has made $7.1M in payments to 21,256 healthcare providers, recorded across 78,555 transactions in the CMS Open Payments database. In 2022, the company paid $3.0M. The top product by payment volume is ORGOVYX ($3.1M).
Payments were distributed across 136 medical specialties. The top specialty by payment amount is Urology ($1.2M to 3,349 doctors).
Payment categories include: Food & Beverage ($1.5M), Consulting ($1.1M), Research ($2.0M), Travel & Lodging ($184,990).